ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Polaryx Therapeutics Inc
6.39
-0.0700
-1.08%
盤前:
6.45
0.0600
+0.94%
05:30 EDT
成交量:
5.19萬
成交額:
33.53萬
市值:
3.03億
市盈率:
-32.30
高:
6.85
開:
6.46
低:
6.23
收:
6.46
52周最高:
48.91
52周最低:
2.20
股本:
4,734.33萬
流通股本:
4,734.33萬
量比:
0.46
換手率:
0.11%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.1978
每股收益(LYR):
-0.1978
淨資產收益率:
-193.70%
總資產收益率:
-96.12%
市淨率:
66.27
市盈率(LYR):
-32.30
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Polaryx Therapeutics獲FDA快速通道資格,Plx-200治療晚嬰期神經元蠟樣脂褐質沉積症(CLN2病)
美股速递
·
03/17
Polaryx Therapeutics獲FDA安全許可函,將於2026年第三季度啓動Soteria試驗
美股速递
·
03/17
Polaryx Therapeutics Inc:持續積極攜手合同研究機構推進2026年上半年啓動臨床試驗計劃
美股速递
·
02/17
Polaryx Therapeutics 宣佈直接登陸納斯達克,股票代碼「PLYX」即將開始交易
美股速递
·
02/02
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PLYX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLYX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics Inc","latestPrice":6.39,"timestamp":1776369600000,"preClose":6.46,"halted":0,"volume":51855,"hourTrading":{"tag":"盘前","latestPrice":6.45,"preClose":6.39,"latestTime":"05:30 EDT","volume":492,"amount":3158.7946356,"timestamp":1776418248550,"change":0.06,"changeRate":0.00939,"amplitude":0.089264},"delay":0,"changeRate":-0.010835913312693542,"floatShares":47343297,"shares":47343300,"eps":-0.197809,"marketStatus":"盤前交易","change":-0.07,"latestTime":"04-17 05:36:52 EDT","open":6.46,"high":6.8525,"low":6.23,"amount":335339.491995,"amplitude":0.096362,"askPrice":7.32,"askSize":100,"bidPrice":5.58,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.197809,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776432600000},"marketStatusCode":1,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":6.39,"preHourTrading":{"tag":"盘前","latestPrice":6.45,"preClose":6.39,"latestTime":"05:30 EDT","volume":492,"amount":3158.7946356,"timestamp":1776418248550,"change":0.06,"changeRate":0.00939,"amplitude":0.089264},"postHourTrading":{"tag":"盘后","latestPrice":6.39,"preClose":6.39,"latestTime":"18:46 EDT","volume":104,"amount":658.9589,"timestamp":1776379573902,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.46274399840155556},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","floatShares":47343297,"roa":"-96.12%","roe":"-193.70%","lyrEps":-0.197809,"volumeRatio":0.46274399840155556,"shares":47343300,"dividePrice":0,"high":6.8525,"amplitude":0.096362,"preClose":6.46,"low":6.23,"week52Low":2.201,"pbRate":"66.27","week52High":48.91,"institutionHeld":0,"latestPrice":6.39,"eps":-0.197809,"divideRate":0,"volume":51855,"delay":0,"ttmEps":-0.197809,"open":6.46,"prevYearClose":45,"prevWeekClose":5.68,"prevMonthClose":7.56,"prevQuarterClose":7.56,"fiveDayClose":5.76,"twentyDayClose":5.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLYX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLYX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1773806400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLYX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLYX","date":"2026-04-15","current":-32.303889,"percent":0.294118,"low":-201.755192,"twenty":-37.429735,"median":-31.848498,"eighty":-16.613099,"high":-13.892286,"avg":-36.848897,"sd":32.851081,"marketCap":306311131},"quantilePoints":[{"date":"2026-01-30","current":-58.797227,"twenty":-58.797227,"median":-58.797227,"eighty":-58.797227,"marketCap":482901629},{"date":"2026-02-06","current":-92.230945,"twenty":-129.699766,"median":-109.380137,"eighty":-58.797227,"marketCap":757492752},{"date":"2026-02-13","current":-16.832147,"twenty":-126.529328,"median":-58.797227,"eighty":-25.939953,"marketCap":138242427},{"date":"2026-02-20","current":-15.391039,"twenty":-99.090622,"median":-34.183094,"eighty":-16.79756,"marketCap":126406602},{"date":"2026-02-27","current":-18.388545,"twenty":-65.483971,"median":-21.847205,"eighty":-15.852193,"marketCap":151025117},{"date":"2026-03-06","current":-15.102817,"twenty":-58.797227,"median":-17.581524,"eighty":-15.852193,"marketCap":124039438},{"date":"2026-03-13","current":-26.804618,"twenty":-52.848332,"median":-19.339676,"eighty":-15.932895,"marketCap":220146331},{"date":"2026-03-20","current":-32.569052,"twenty":-39.601662,"median":-22.827159,"eighty":-16.059713,"marketCap":267489628},{"date":"2026-03-27","current":-33.617166,"twenty":-34.863297,"median":-29.312147,"eighty":-16.128886,"marketCap":302050234},{"date":"2026-04-02","current":-40.045527,"twenty":-39.919067,"median":-31.906143,"eighty":-16.140415,"marketCap":359809057},{"date":"2026-04-10","current":-30.350294,"twenty":-38.506935,"median":-31.819676,"eighty":-16.417108,"marketCap":272697390},{"date":"2026-04-15","current":-34.091389,"twenty":-37.429735,"median":-31.848498,"eighty":-16.613099,"marketCap":306311131}],"updateTime":1776411992449},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLYX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1194971558","title":"Polaryx Therapeutics獲FDA快速通道資格,Plx-200治療晚嬰期神經元蠟樣脂褐質沉積症(CLN2病)","url":"https://stock-news.laohu8.com/highlight/detail?id=1194971558","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194971558?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 20:33","pubTimestamp":1773750788,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics公司宣布,其研发的药物Plx-200已获得美国食品药品监督管理局(FDA)授予的快速通道资格,用于治疗晚婴期神经元蜡样脂褐质沉积症(CLN2病)。这一资格将加速该药物的研发和审评进程,为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139785167","title":"Polaryx Therapeutics獲FDA安全許可函,將於2026年第三季度啓動Soteria試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1139785167","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139785167?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 20:31","pubTimestamp":1773750679,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics, Inc. 宣布,在获得美国食品药品监督管理局(FDA)的\"安全进行\"许可函后,公司计划于2026年第三季度正式启动Soteria临床试验。\n这一进展标志着Polaryx Therapeutics在药物研发道路上迈出关键一步。FDA的许可函确认了试验方案的安全性,为Soteria试验的开展扫清了监管障碍。公司预计,该试验将为其在研疗法提供重要临床数据支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156072440","title":"Polaryx Therapeutics Inc:持續積極攜手合同研究機構推進2026年上半年啓動臨床試驗計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1156072440","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156072440?lang=zh_tw&edition=fundamental","pubTime":"2026-02-17 21:34","pubTimestamp":1771335254,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics Inc(简称PLYX)近日透露,公司正与其合同研究机构(CRO)保持紧密合作,全力推进相关临床试验的筹备工作。根据最新规划,该项试验预计将于2026年上半年正式启动。\n目前,双方团队正就试验方案设计、监管审批流程及执行细节等关键环节进行深入协调。这一进展标志着Polaryx Therapeutics Inc在创新药物研发领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138471055","title":"Polaryx Therapeutics 宣佈直接登陸納斯達克,股票代碼「PLYX」即將開始交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1138471055","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138471055?lang=zh_tw&edition=fundamental","pubTime":"2026-02-02 21:33","pubTimestamp":1770039190,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics 已正式宣布,公司将通过直接上市方式登陆纳斯达克交易所。其普通股预计将于近期开始公开交易,股票交易代码定为“PLYX”。此次直接挂牌意味着该公司不发行新股,而是由现有股东直接将其持有的股份在公开市场进行交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PLYX\",params:#limit:6,delay:false,,,undefined,":[]}}